{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:17:12Z","timestamp":1775207832385,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantationreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.trre.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T06:30:47Z","timestamp":1409121047000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?"],"prefix":"10.1016","volume":"29","author":[{"given":"Hallvard","family":"Holdaas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Potena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faouzi","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2014.08.003_bb0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIR.0b013e31823eb07a","article-title":"Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"126","author":"Lentine","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2014.08.003_bb0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.tp.0000235527.81917.fe","article-title":"Cardiovascular complications after renal transplantation and their prevention","volume":"82","author":"Ojo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1681\/ASN.2004070580","article-title":"Incidence and predictors of myocardial infarction after kidney transplantation","volume":"16","author":"Lentine","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2014.08.003_bb0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1681\/ASN.2005090984","article-title":"Acute myocardial infarction and kidney transplantation","volume":"17","author":"Kasiske","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2014.08.003_bb0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/lt.20722","article-title":"Validation of cardiovascular risk scores in a liver transplant population","volume":"12","author":"Guckelberger","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0030","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/lt.23508","article-title":"Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies","volume":"18","author":"Madhwal","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12023","article-title":"OPTN\/SRTR 2011 Annual Data Report: heart","volume":"13","author":"Colvin-Adams","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0040","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.healun.2013.08.009","article-title":"International Society for Heart and Lung Transplantation. ISHLT International Registry for Heart and Lung Transplantation\u2014into the fourth decade, from strength to strength","volume":"32","author":"Stehlik","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0060","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/01.TP.0000160764.35083.B8","article-title":"Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial","volume":"79","author":"Fellstrom","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0045","first-page":"263","article-title":"Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for lipid management in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.trre.2014.08.003_bb0065","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2014.08.003_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ahj.2009.05.036","article-title":"The prognostic importance of modifiable risk factors after heart transplantation","volume":"158","author":"Arora","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.trre.2014.08.003_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized, long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (Neoral)\/sirolimus in renal transplantation. II. Survival, function and protocol compliance at one year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0070","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0080","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/lt.20602","article-title":"Cardiovascular risk factors after liver transplantation","volume":"11","author":"Mu\u00f1oz","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00129784-200202060-00003","article-title":"Strategies for minimizing hyperlipidemia after cardiac transplantation","volume":"2","author":"Kirklin","year":"2002","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.trre.2014.08.003_bb0090","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/0002-9149(94)90856-7","article-title":"Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors","volume":"74","author":"Escobar","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trre.2014.08.003_bb0095","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/j.1600-6143.2009.02696.x","article-title":"Use of cardioprotective medications in kidney transplant recipients","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0100","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.mce.2012.10.030","article-title":"The immunosuppressive agents rapamycin, cyclosporine A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue","volume":"365","author":"Pereira","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.trre.2014.08.003_bb0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1194\/jlr.M021485","article-title":"Major involvement of mTOR in the PPAR\u04af-induced stimulation of adipose tissue lipid uptake and fat accretion","volume":"53","author":"Blanchard","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trre.2014.08.003_bb0115","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.tp.0000286095.55685.e9","article-title":"Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia","volume":"84","author":"Ma","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2007.06.016","article-title":"The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes","volume":"56","author":"Brown","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.trre.2014.08.003_bb0125","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trre.2014.08.003_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model","volume":"2","author":"Blum","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2014.08.003_bb0140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0145","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0041-1345(03)00241-0","article-title":"Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation","volume":"35","author":"Legendre","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.08.003_bb0150","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study","volume":"6","author":"Vitko","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0165","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/TP.0b013e31825b411c","article-title":"A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor","volume":"94","author":"Gurk-Turner","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.trre.2013.03.002","article-title":"Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?","volume":"27","author":"Zuckermann","year":"2013","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2014.08.003_bb0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1year","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0180","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0185","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/TP.0b013e318291a269","article-title":"A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients","volume":"95","author":"Flechner","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0190","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/ndt\/gfp778","article-title":"Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study","volume":"25","author":"Ekberg","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0195","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0205","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07315724.2008.10719668","article-title":"The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk","volume":"27","author":"Fernandez","year":"2008","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.trre.2014.08.003_bb0215","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0220","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0225","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2014.08.003_bb0230","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0235","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3months after renal transplantation: CONCEPT study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0240","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/TP.0b013e3181821c25","article-title":"Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus","volume":"86","author":"Morales","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0245","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/lt.23658","article-title":"Calcineurin inhibitor-free mycophenolate mofetil\/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0250","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation \u2013 PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0255","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1600-6143.2010.03128.x","article-title":"Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function","volume":"10","author":"Masetti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0260","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0265","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1600-6143.2011.03919.x","article-title":"Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial","volume":"12","author":"Abdelmalek","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0270","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0275","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.tp.0000261630.63550.41","article-title":"Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial","volume":"83","author":"Shenoy","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0280","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis","volume":"17","author":"Saliba","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0285","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/lt.21314","article-title":"A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function","volume":"13","author":"Watson","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.08.003_bb0290","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early withdrawal of calcineurin inhibitor therapy in de novo heart transplant recipients \u2013 a multicenter, randomized Scandinavian trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0295","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0300","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":"Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0305","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0310","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/TP.0b013e3181fd01b7","article-title":"Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial","volume":"90","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0315","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.healun.2012.01.002","article-title":"Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study","volume":"31","author":"Potena","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0320","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2014.08.003_bb0325","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2004.08.074","article-title":"Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)","volume":"95","author":"Costa","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trre.2014.08.003_bb0330","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007890-200002270-00006","article-title":"SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts","volume":"69","author":"Viklick\u00fd","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0335","doi-asserted-by":"crossref","first-page":"H2721","DOI":"10.1152\/ajpheart.01174.2006","article-title":"Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells","volume":"292","author":"Ma","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.trre.2014.08.003_bb0340","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.108.144147","article-title":"Everolimus inhibits monocyte\/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits","volume":"328","author":"Baetta","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trre.2014.08.003_bb0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2006.11.023","article-title":"Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM","volume":"195","author":"Goueffic","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.trre.2014.08.003_bb0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR _\/_ mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.trre.2014.08.003_bb0355","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1476-5381.2008.00102.x","article-title":"Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels","volume":"156","author":"Chen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.trre.2014.08.003_bb0360","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jacc.2006.09.047","article-title":"Selective clearance of macrophages in atherosclerotic plaques by autophagy","volume":"49","author":"Verheye","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trre.2014.08.003_bb0365","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jchf.2013.07.002","article-title":"Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus or mycophenolate mofetil randomized, multicenter trial","volume":"1","author":"Kobashigawa","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.trre.2014.08.003_bb0370","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2014.08.003_bb0375","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1600-6143.2011.03767.x","article-title":"Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression","volume":"11","author":"McKenna","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0380","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years","volume":"4","author":"Flechner","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0385","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jacc.2005.02.035","article-title":"Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years","volume":"45","author":"Kobashigawa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trre.2014.08.003_bb0390","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.111.176594","article-title":"Aortic stiffness and central wave reflections predict outcome in renal transplant recipients","volume":"58","author":"Verbeke","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.trre.2014.08.003_bb0395","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11906-009-0019-4","article-title":"Aortic stiffness, kidney disease, and renal transplantation","volume":"11","author":"Bahous","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.trre.2014.08.003_bb0400","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/HJH.0b013e32830ef940","article-title":"Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients","volume":"26","author":"Seckinger","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.trre.2014.08.003_bb0405","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1600-6143.2011.03697.x","article-title":"Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine","volume":"11","author":"Joannid\u00e8s","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5301\/jn.5000044","article-title":"Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction","volume":"25","author":"Paoletti","year":"2012","journal-title":"J Nephrol"},{"key":"10.1016\/j.trre.2014.08.003_bb0415","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/TP.0b013e318189049a","article-title":"Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft","volume":"86","author":"Raichlin","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0420","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/eurheartj\/ehn407","article-title":"Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients","volume":"29","author":"Kushwaha","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trre.2014.08.003_bb0425","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3182332886","article-title":"Everolimus prevents endomyocardial remodeling after heart transplantation","volume":"92","author":"Hiemann","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0430","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: observational results 3years after transplantation","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0435","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: three-year analysis","volume":"81","author":"Ciancio","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0440","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1600-6143.2012.04036.x","article-title":"Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER Study","volume":"12","author":"Lebranchu","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0445","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.tp.0000243152.19789.0e","article-title":"The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation","volume":"82","author":"Eisen","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0450","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1432-2277.2010.01140.x","article-title":"Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?","volume":"24","author":"Zeier","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.08.003_bb0455","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/01.tp.0000268810.61393.2c","article-title":"Prognostic importance of renal function 1year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy","volume":"84","author":"Arora","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.08.003_bb0460","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1517\/14740338.2012.722993","article-title":"A drug safety evaluation of everolimus in kidney transplantation","volume":"11","author":"Holdaas","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.trre.2014.08.003_bb0465","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jhep.2011.06.015","article-title":"m-TOR inhibitors: what role in liver transplantation?","volume":"55","author":"Kawahara","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.trre.2014.08.003_bb0470","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1358\/dot.2009.45.1.1313982","article-title":"Everolimus in liver and lung transplantation","volume":"45","author":"Koch","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.trre.2014.08.003_bb0475","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.trre.2010.01.005","article-title":"Clinical recommendations for the use of everolimus in heart transplantation","volume":"24","author":"Manito","year":"2010","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2014.08.003_bb0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"mTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"Diekmann","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2014.08.003_bb0490","first-page":"CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"2","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2014.08.003_bb0495","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2014.08.003_bb0500","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.08.003_bb0505","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/00912700222011148","article-title":"Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus","volume":"42","author":"Kovarik","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2014.08.003_bb0510","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.tp.0000262706.28513.6a","article-title":"Reducing the risks of cardiovascular disease in liver allograft recipients","volume":"83","author":"Mells","year":"2007","journal-title":"Transplantation"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X14000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X14000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T19:18:18Z","timestamp":1598210298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X14000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0955470X14000597"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2014.08.003","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}